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of extrinsinc factors include unadapted material, bad training 
planification, or usage of some drugs (quinolones, corticoids,…) [4]. Some patients are refractory to the traditional treatments 
(including physiotherapy, shockwaves, deep transverse massage, 
etc.) and thus need another option. Less invasive than surgery, 
Platelet-Rich Plasma (PRP) injection has become more and more 
popular over the last decades, particularly in sports medicine [5-7]. In this paper, in addition of presenting the data asserting 
the effectiveness of injections of reproducible PRP collected from an apheresis machine on different tendinopathies, we introduce 
another original contribution : the  investigation of the possible 
correlation between several biomarkers and healing evolution to determine the factors of good prognosis, if any.
Material and Methods
Forty-eight patients (mean age = 49 y.o +/- 10 y.o, min 
= 26 y.o, max = 77 y.o. ; 15 women and 33 men) afflicted with 
different pathologies participated in this study after they gave 
their informed consent (lateral epicondylitis (n=20), medial 
epicondylitis (n=3), tendinopathy of the gluteus medius (n=1), 
patellar tendinopathy (n=6), calcaneal tendinopathy (n=14), and 
plantar fasciitis (n=4)). To be recruited, the patients have had to 
suffer from a chronic tendinopathy for more than 3 months and be refractory to the following classical treatments : non steroidal 
anti inflammatory drugs, electrotherapy, deep transverse 
massage, eccentric revalidation and shockwaves therapy. A 
clinical examination was carried out to confirm the diagnosis and to exclude any other pathology, including metabolic disease. 
After this first step, a blood sample was drawn and analyzed 
to quantify the presence of various metabolic biomarkers 
(glycemia, thyroid hormons, cholesterolemia, uricemia) which 
are considered to be risk factors of tendinopathies.  The initial 
pain assessment was made using a Visual Analogic Scale (VAS) 
of pain and a pressure algometer (Commander Algometer, Tech 
Medical) prior to the PRP collection. The PRP collection and 
injection protocol used has already been described in previous 
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Background : The aims of this study were to evaluate the effect 
of  a single PRP injection followed by a standardized reeducation protocol among patients suffering from different tendinopathies, but 
otherwise healthy,  and to determine the biomarkers that constitute good prognosis factors, if any.
Methods : 48 patients suffering from different tendinopathies 
and refractory to conventional physiotherapy were treated with a 
single PRP injection.  Prior to the injection, a blood sample was drawn 
and some biological parameters (glycemia, cholesterolemia,…) were 
measured. A pain assessment was then made using a Visual Analog Scale of pain (VAS) and a pressure algometer. The same assessment 
was carried out after 6 weeks and 12 weeks when possible. 
Results : There is an overall significant improvement in VAS 
score at the end of the 12 weeks follow- up. However, no correlation 
was found between the evolution of the clinical scores and the biological parameters measured.
Conclusion: A PRP injection followed by a program of eccentric 
rehabilitation positively affects the algo-functional scores of patients 
with tendinopathies who were refractory to conventional physio-
therapy, whatever the initial values of the measured biological pa-rameters.
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Introduction
Tendinopathies represent a significant part of musculoskeletal 
injuries [1]. They are generally caused by microtraumae 
following a mechanical overload due to work or sport activities. 
Inflammation, like rhumatoid polyarthritis or spondylarthritis, 
can also result in tendon injury. Several factors can facilitate the onset of the tendinopathy, which can be either intrinsic or 
extrinsinc [2]. Amongst the former, we can distinguish between 
those that can be altered (hyperucemia, hypercholesterolemia, 
chondrocalcinosis, disthyroidis, degenerative rheumatism, 
infection,...) [3] and those that cannot (age, gender,...). Examples 
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reports [8-10]. Briefly, the platelets are extracted using an 
apheresis machine (TEC.COM, Fresenius Kabi) which can lead to a 
reproducible platelet concentration of 850 000 units/microlitre, 
a value approximatively 4 times as high as in the whole blood 
[11].  6 millilitres of this PRP were mixed with 300 microlitres of calcium chloride to activate the platelets. The injection was performed under ultrasound guidance and without local 
anaesthesia as it could decrease PRP healing effectiveness. The 
physiotherapy started 5 days after the injection, 3 times a week 
for 6 weeks [12]. The pain was reassessed 6 weeks and 12 weeks 
after the injection. For the statistical processing of these results, 
a Shapiro-Wilk test was made to evaluate the normal distribution of the data and a paired Welch test was used to compare the 
results of the VAS and the algometer at the different time points. 
Linear mixed effects models (nlme package, RStudio, Rstudio 
Inc.) were used to investigate the potential relationship between 
the biological parameters and the clinical evolution (evaluated by 
VAS and algometer scores).
Results
When combining the results for all the tendons, a significant 
decrease of the VAS score was noted after 6 weeks (VAS0 = 
4.81, ΔVAS0-6 = -0.84 ; p = 0.007) and after 12 weeks (VAS0 = 
4.81, ΔVAS0-12 = -1.1 ; p=0.01). The result of the algometer also 
improved significantly between the 6th and the 12th week (Algo6 
= 52.8 N/cm2, ΔAlgo6-12 = 12.9 N/cm2 ; p<0.05). Another way to 
look at the results is to observe that 70 % of the patients showed 
a positive effect following the PRP injection with a decrease of 
pain of at least 1 point on the VAS (Fig. 1).  For 25 % of them, 
the decrease was at least 4 points. Independently, 40 % of the 
patients saw their algometer result increase by more than 30N/cm2 by the end of the 12 week follow-up (Fig. 2). A tendon-specific 
analysis was also performed. Statistically significant results were only found for the groups of patients suffering from epycondilitis 
(ΔVAS0-12 = -1.69, p<0.005) and Achilles tendinopathy (ΔVAS0-
6 = -1.96, p<0.005). The sample size of the other tendinopathies 
was too small to observe a statistically significant evolution.
A possible correlation between hypercholesterolemia and 
hyperglycemia and the evolution of VAS and algometer results 
was investigated (all the other biomarkers were in the normal 
range for all the patients). Such a correlation was not observed. 
Furthermore, no statistically significant differences in ΔVAS0-12 
and ΔAlgo0-12 were found after clustering the patients into two 
groups, one with normal  and one with elevated cholesterolemia 
(Fig. 3) and glycemia (Fig. 4) .
Discussion
This study quantitatively confirmed the effectiveness of 
a single PRP injection followed by an eccentric  revalidation 
for patients suffering from various tendinopathies refractory 
to conventional treatments, as shown by the 23 % decrease in 
ΔVAS0-12 and 24 % increase in ΔAlgo6-12. The tendon-specific 
results have too few data points to show statistical significance, 
but the trend observed is encouraging and confirms the results found in the literature. Indeed, in the case of epicondylitis, an 
algofunctional improvement was noticed as previously reported. 
Figure 1: Cumulative histogram of the evolution of the VAS score for 
the 48 patients over the 12 weeks clinical trial.  The pain decreased for 
70% of the patients, 10% saw no difference and the pain increased for 
20%.
Figure 2: Cumulative histogram of the evolution of the algometre score 
for the 48 patients over the 12 weeks clinical trial.  All patients saw an 
improvement of their score which reached 30 N/cm2 for more than 
50%.
Figure 3: Evolution of the VAS score over the 12 weeks clinical trial 
with respect to cholesterolemia - whisker plot.  23 patients had a nor-
mal level and 24 presented hypercholesterolemia.
Figure 4: Evolution of the VAS score over the 12 weeks clinical trial 
with respect to glycemia - whisker plot.  28 patients had a normal level 
and 18 presented hyperglycemia.
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[13, 14]. The follow-up in those studies lasted  24 weeks and 28 
months respectively. As for Achilles tendinopathy, several other studies also demonstrated a decrease in pain following a PRP 
injection [15-17].  To the authors’ opinion, the lack of significant 
results in the tendon-specific part of the present study is therefore due to the small number of patients recruited. Furthermore, no 
follow-up information could be obtained from several patients. Despite all the studies mentioned point in the same direction, 
it is difficult to compare them as the PRP collection protocols 
might be quite different. Indeed, the collection itself might be performed using laboratory or commercial machines, or also 
an apheresis machine. The amount of platelets will then vary according to the extraction method and is not repeatable in the 
case of the commercial technique [18, 19]. This study presents, to 
the best of the authors’ knowledge, the first attempt to correlate 
biomarkers as factors of good prognosis to the evolution of the 
recovery.  Hyperglycemia and  especially type II diabetes, leads 
to a disorganization of collagen fibers, and an increase in tendons 
thickness  and volume [20] ; hyperthyroidism  increases collagen catabolism and hypothyroidism leads to a decreased collagen 
metabolism [21]; hypercholesterolemia impairs the tendon extra 
cell matrix and thus alters its biomechanical properties [22] and 
finally, hyperucemia could cause an inflammation provoking the 
degeneration of the tendon tissue [23].  It might then be surprising 
that no correlation was found between the values of the biological 
markers and the evolution of the tendons healing evaluated by 
the VAS and the algometer. However, one has to distinguish 
between the correlation between the values of the markers and 
the susceptibility of developing a tendinopathy compared to the susceptibility of slower healing once the pathology has triggered. 
The former is out of the scope of the present report.  From our results, it seems that the initial glycemia and cholesterolemia 
don’t have any influence on the prognosis of  the evolution of the 
tendinopathy. In a previous report [8], a young age of the patients 
(<30 years old) and a better strength of the quadriceps before 
infiltration were identified as good prognosis factors to recover 
from a jumper’s knee while diabetes was a bad one [24]. 
Further studies should focus on comparing the effectiveness of 
the PRP treatment for different tendinopathies, which couldn’t 
be established in the present study because of the relative small 
number of patients afflicted with different pathologies. The total 
number of patients was however sufficient to  obtain statistically 
significant results regarding the effectiveness of a single PRP 
injection in the treatment of tendinopathies. Other good prognosis 
factors, like biomechanical ones, should be investigated too.
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